Shandong Cancer Hospital and Institute: Carcinoma, Non-Small-Cell Lung trials

The registry lists 14 Carcinoma, Non-Small-Cell Lung studies with Shandong Cancer Hospital and Institute as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 10Phase 3 2Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLCRecruitingNCT06241807Phase 2
• A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs TreatmentActive, not recruitingNCT07669051Phase 2
• A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLCStatus unknownNCT04982549Phase 2
• A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung CancerTerminatedNCT04958993Phase 1/2
• A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer PatientsStatus unknownNCT04619563Phase 2
• A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung CancerStatus unknownNCT04619537Phase 2
• A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line TreatmentStatus unknownNCT04560244Phase 2
• Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLCStatus unknownNCT03884192Phase 3
• Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC PatientsStatus unknownNCT03672136Phase 2
• A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLCStatus unknownNCT03557411Phase 2
• Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC PatientsStatus unknownNCT03489616Not applicable
• Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790MStatus unknownNCT02972333Phase 3
• Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung CancerStatus unknownNCT02195453Phase 4
• Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung CancerStatus unknownNCT02191059Phase 2